Automated Insulin Delivery in Pregnant Patients With Type 1 Diabetes With Extension Into Outpatient at Home
- Conditions
- PregnancyType 1 Diabetes
- Interventions
- Device: Automated Insulin Delivery
- Registration Number
- NCT04492566
- Lead Sponsor
- Sansum Diabetes Research Institute
- Brief Summary
This clinical trial is a safety and feasibility study to assess the performance of an artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the iAPS platform for pregnant patients with type 1 diabetes (T1D).
- Detailed Description
The system will be evaluated on up to 21 pregnant adult subjects with type 1 diabetes age 18-45 years old at three clinical sites (Sansum Diabetes Research Institute, Mayo Clinic Rochester MN and Mt Sinai Hospital, New York City). Subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present. During the session, subjects will bolus for all meals and snacks, and will perform their usual daily activities while being accompanied by study medical staff.
For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 10
- Age ≥ 18 and ≤ 45 years at the time of screening.
- Clinical diagnosis of type 1 diabetes
- Currently using an insulin pump at the time of screening.
- HbA1c ≤ 9%, as performed by point of care or central laboratory testing.
- Pregnant 14+0/7 to 32+6/7 weeks gestation.
- Singleton pregnancy without any other significant known complications, such as preeclampsia, premature rupture of membranes, 2nd/3rd trimester bleeding, fetal growth or fluid abnormalities.
- No proven or suspected fetal malformations diagnosed in the current pregnancy.
- Bolus for all meals and snacks that contain ≥ 5 grams of carbohydrate.
- Willing to switch to, or continue Novolog or Humalog for the closed-loop session.
- Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.
- Willing to abide by the study protocol and use study-provided devices.
- Have a care partner with the following responsibilities: knowing subject whereabouts and being promptly available for contact by study staff during the day and night, residing in the same dwelling as subject during the night, being agreeable to all device training during the supervised HCL session and additional training on hyper- and hypoglycemia treatment, and assisting with emergency care if needed, such as transportation to the hospital or emergency department.
-
Known unstable cardiac disease or untreated cardiac disease, as revealed by history or physical examination.
-
Concurrent use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas).
-
Hemophilia or any other bleeding disorder
-
Prior history of Preterm Premature Rupture of Membranes (PPROM)
-
Significant hyperemesis interfering with carbohydrate intake
-
Laboratory results:
- A1C > 9%
- Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, creatinine > 1.5 mg/dL)
- Liver and renal function testing drawn at screening visit or within three months prior to screening (for other purposes) will suffice for enrollment purposes
-
Dermatological conditions that would preclude wearing a CGM sensor or infusion site.
-
Any condition that could interfere with participating in the trial, based on investigator judgment.
-
Participation in another pharmaceutical or device trial at the time of enrollment or during the study.
-
Having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
-
History of severe hypoglycemia in the past 6 months
-
History of DKA requiring hospitalization in the past 6 months
-
Significant chronic kidney disease (eGFR < 60) or hemodialysis
-
Significant liver disease
-
History of adrenal insufficiency
-
History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated
-
History of high dose steroid use in the past 8 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description AID Evaluation Automated Insulin Delivery After completing a 1-2 week CGM run-in period, subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present. For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy.
- Primary Outcome Measures
Name Time Method Time in Target Glucose Range Duration of iAPS Use During Pregnancy up to 40 weeks of Use Time in target glucose range 63-140 mg/dL measured by CGM to determine safety and efficacy of the integrated system
- Secondary Outcome Measures
Name Time Method Glucose > 180 mg/dL Duration of iAPS Use During Pregnancy up to 40 weeks of Use Percent time GGM glucose \> 180 mg/dL
Glucose < 63 mg/dL Duration of iAPS Use During Pregnancy up to 40 weeks of Use Percent time CGM glucose \< 63 mg/dL
Glucose > 140 mg/dL Duration of iAPS Use During Pregnancy up to 40 weeks of Use Percent time GGM glucose \> 140 mg/dL
Glucose < 54 mg/dL Duration of iAPS Use During Pregnancy up to 40 weeks of Use Percent time CGM glucose \< 54 mg/dL
Hypoglycemic Events Per Week Duration of iAPS Use During Pregnancy up to 40 weeks of Use Number of hypoglycemic events per week, defined as time \<54 mg/dL for 15 consecutive minutes followed by time \>70 mg/dL for 15 consecutive minutes.
Overnight Time in Target Glucose Range Duration of iAPS Use During Pregnancy up to 40 weeks of Use Sensor glucose time within the target range of 63-140 mg/dl overnight
Hyperglycemic Events Duration of iAPS Use During Pregnancy up to 40 weeks of Use Number of episodes with ketones \>1 mmol/L
Serious Adverse Events (SAE) Duration of iAPS Use During Pregnancy up to 40 weeks of Use The total number of serious adverse events during the clinical trial
Adverse Device Effects (ADE) Duration of iAPS Use During Pregnancy up to 40 weeks of Use The total number of adverse device effects (ADE) during the clinical trial
Postprandial Time in Target Glucose Range Duration of iAPS Use During Pregnancy up to 40 weeks of Use Sensor glucose time within the target range of 63-140 mg/dl postprandially within 2 hours following meals and 2 hours following meals
Severe Hypoglycemic Events Duration of iAPS Use During Pregnancy up to 40 weeks of Use Number of hypoglycemic events that events that require active assistance of another individual
Glucose > 250 mg/dL Duration of iAPS Use During Pregnancy up to 40 weeks of Use Percent time GGM glucose \> 250 mg/dL
Serious Adverse Device Events (SADE) Duration of iAPS Use During Pregnancy up to 40 weeks of Use The total number of serious adverse events related to the study device use during the clinical trial
Unanticipated Adverse Device Effects (UADE) Duration of iAPS Use During Pregnancy up to 40 weeks of Use The total number of unanticipated adverse device effects (UADE) during the clinical trial
Mean CGM Glucose Level Duration of iAPS Use During Pregnancy up to 40 weeks of Use Mean CGM glucose level during AID use
Trial Locations
- Locations (3)
Sansum Diabetes Research Institute
🇺🇸Santa Barbara, California, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States